Core Insights - VivoSim Labs, Inc. has appointed Dr. Amar Sethi as Chief Scientific Officer to enhance its scientific strategy and capabilities in drug testing and toxicology [1][5] Company Overview - VivoSim Labs is a pharmaceutical and biotechnology services company focused on testing drugs in three-dimensional human tissue models, specifically for liver and intestine [6] - The company anticipates increased adoption of its human tissue models following FDA's announcement to refine animal testing requirements in favor of non-animal methods [6] Leadership Appointment - Dr. Amar Sethi brings three decades of experience in pharmaceutical drug development, CRO leadership, and diagnostic innovation [2] - His previous roles include leading global clinical programs and developing FDA-qualified biomarker platforms, contributing to significant business growth [4] Strategic Focus - Dr. Sethi will lead initiatives in toxicology, translational models, and bioanalytics, aiming to enhance multi-parametric toxicity prediction using human-relevant systems [3] - The company aims to integrate advanced 3D biology with AI-driven analytics to provide earlier decision-ready insights for sponsors [5] Market Positioning - VivoSim Labs is positioned to be a preferred scientific partner as the industry increasingly adopts 3D NAM systems for drug development [5]

Core Insights - VivoSim Labs has appointed Tony Lialin as Chief Commercial Officer to enhance its AI-enabled NAMkind™ liver and intestine toxicology services in a growing market [1][2] - The global market for liver and gastrointestinal in-vitro models and toxicology services generated $641 million in revenue in 2024, with services accounting for 53.1% of this revenue [3] - The U.S. market for liver toxicology models and services is valued at $325 million, representing 50.8% of the global market [3] Market Opportunity - The global in vitro liver model market is experiencing a growth rate of 5.9% CAGR from 2020 to 2024, indicating increasing adoption of 3D human-relevant systems [3] - Regulatory changes, such as the FDA Modernization Act 2.0, are driving the adoption of non-animal methodologies, which supports the use of human-relevant in vitro models for ADME and toxicology [4] Technology and Services - VivoSim Labs utilizes AI to enhance the analysis of multi-parametric toxicity signatures in liver and intestinal organoid assays, improving the reliability of dose-response analyses [5] - The company's NAMkind™ models are designed to provide critical toxicology insights earlier in the drug development process, aiming to streamline pre-IND decision-making [6] Company Overview - VivoSim Labs focuses on testing drugs and drug candidates using 3D human tissue models of the liver and intestine, offering insights through its NAM models [7] - The company anticipates increased adoption of its human tissue models following recent FDA announcements aimed at refining animal testing requirements [7]